The subject has received another investigational agent within  days of the first dose of study drug
The subject has received any other type of investigational agent within  days before the first dose of study treatment
The participant has received any other type of investigational agent within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
The participant has received another investigational agent within  days of the first dose of study drug
Received any investigational agent within the  days before the start of study treatment (st dose of fludarabine)
The subject has received any other type of investigational agent within  days before the first dose of study treatment
Received another investigational agent (defined as any agent/device that has not received regulatory approval for any indication) within  days of the first dose of study drug for a nonmyelosuppressive agent, or  days of the first dose of study drug for a myelosuppressive agent
Received any investigational agent within the  days before the start of study treatment (st dose of fludarabine phosphate [fludarabine])
Received any investigational agent within the  days before the start of study treatment (st dose of fludarabine)
mCRPC EXPANSION COHORT: The patient has received any other type of investigational agent within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
At least  days after the last dose of a biologic agent.
Receipt of any other type of investigational agent within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
Any other type of investigational agent within  weeks before the first dose of study treatment
RENAL COHORT: The subject has received any other type of investigational agent within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
Any other type of investigational agent within  days before the first dose of study treatment
Any anti-cancer treatment within  days or any investigational agent within  days before the first dose of study drug.
Investigational agent received within  days prior to the first dose of study drug
The subject has received any other type of investigational agent within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
Having received an investigational agent within  days prior to the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
The participant has received any other type of investigational agent within  days before the first dose of study treatment
Treatment with any investigational agent within  days before the first dose of study treatment
Having received an investigational agent with  days of receiving the first dose of study drug on this trial
Use of any other type of investigational agent or treatment concurrently or within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
The subject has received any other type of investigational agent within  days before the first dose of study treatment
The subject has received any investigational agent within  days before the first dose of study treatment
Received any investigational agent within the  days before the start of study treatment (st dose of ALT-)
